세계의 DNases, 리가아제, RNA 중합효소 시장 규모, 점유율, 동향 분석 리포트 : 응용별(DNases : 바이오의약품 가공, Ligases : 올리고뉴클레오티드 합성), 지역별, 부문별 예측(2022-2030년)

DNases, Ligases, And RNA Polymerases Market Growth & Trends:

The global DNases, ligases, and RNA polymerases market size is expected to reach USD 1.28 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.58% from 2022 to 2030. Increasing research and development expenditure is one of the key factors fueling market growth. Furthermore, rising biopharmaceutical production along with a focus on DNA-related innovations is expected to positively impact the global DNases market growth over the forecast period.

For instance, in June 2020, Alphazyme and Codexis entered into a strategic partnership to provide novel enzymes for diagnostics and research. DNases have continued to garner a significant market share in recent years owing to factors such as an increase in the adoption of DNA enzymes related to pharmaceuticals, which are essential for the treatment of various chronic disorders and digestive diseases. In addition, developments in the biotechnology and pharmaceutical fields, such as the introduction of genetic and protein engineering, have helped in expanding applications of enzymes, which is expected to offer lucrative growth opportunities in the forecast period.

An increase in R&D investments to develop ligases as the target for therapeutic applications in cancer is estimated to drive the segment in the forecast period. In addition, strategic activities by major manufacturers will offer lucrative growth opportunities in the projected period. Other factors augmenting segment growth include advancements in healthcare, increasing demand for modernization in the field of medical academics and life sciences, growing investments by governments to develop genomic technologies, and a surge in the demand for oligonucleotide synthesis by private and public research firms.

The COVID-19 pandemic situation has offered lucrative opportunities for RNA polymerase applications. Currently, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications. Many mRNA vaccines are approved for emergency use in many countries across the globe.

For instance, Moderna's mRNA-1273 and BioNTech/ Pfizer BNT-162 vaccines have been approved for use across various regions globally. Moreover, there are instances of huge capital investments for the development of mRNA vaccines. For instance, in June 2021, Sanofi declared an investment of around USD 452.12 annually for its mRNA vaccines development center.

DNases, Ligases, And RNA Polymerases Market Report Highlights:

• By DNAse application, the other applications segment dominated the market in 2021 due to a rise in DNA-based research, an increase in research funding, and reliable utility of DNase in applications

• By ligase application, the other applications segment held the maximum share in 2021. Certain factors such as the rising use of ligases in gene therapies and growth in DNA sequencing are expected to play a major role in the segment growth during the forecast period

• By RNA polymerases application, mRNA production dominated the market in 2021 due to increasing demand for mRNA-based vaccines for COVID-19 and research activities. For instance, Moderna is set to expand its mRNA vaccine pipeline with three new development programs. The programs will target the varicella-zoster virus (VSV), herpes simplex virus (HSV), and a novel checkpoint cancer vaccine

• North America dominated the global market in 2021 owing to increasing demand for gene therapy, rise in the number of genetic disorders and cancer, the presence of research institutes, rising research funding for research on novel gene therapy, and rise in the demand for DNA-based vaccine production for COVID-19

• Asia Pacific is expected to grow considerably in the future owing to the rising prevalence of genetic disorders, rising demand for gene therapy, and high population density

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation & Scope
  • 1.1.1 DNases Application
  • 1.1.2 Ligases Application
  • 1.1.3 Dnases Application
  • 1.1.4 Applications Scope
    • 1.1.4.1 Other Applications Of Dnases
    • 1.1.4.2 Other Applications Of Ligases
    • 1.1.4.3 Other Applications Of Rna Polymerases
  • 1.1.5 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Market Formulation & Validation
  • 1.4.2 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.6.2 Volume Price Analysis (Model 2)
    • 1.6.2.1 Approach 2: Volume Price Analysis
• 1.7 List Of Sources
  • 1.7.1 Primary Sources
  • 1.7.2 Secondary Sources
• 1.8 Objectives
  • 1.8.1 Objective 1:
  • 1.8.2 Objective 2:

Chapter 2 Executive Summary

• 2.1 Market Outlook: Dnases
  • 2.1.1 Competitive Insights
• 2.2 Market Outlook: Ligases
  • 2.2.1 Competitive Insights
• 2.3 Market Outlook: Rna Polymerases
  • 2.3.1 Competitive Insights

Chapter 3 DNases Market: Application Business Analysis

• 3.1 Definitions & Scope
• 3.2 DNases Market: Application Trend Analysis
• 3.3 DNases Market: Application Movement Analysis
• 3.4 Biopharmaceutical Processing
  • 3.4.1 Biopharmaceutical Processing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 3.5 Other Applications
  • 3.5.1 Other Applications Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 4 DNases Market: Competitive Landscape

• 4.1 Market Participation Categorization
• 4.2 Strategy Framework
• 4.3 Vendor Landscape
  • 4.3.1 List Of Key Distributors And Channel Partners
  • 4.3.2 Key Customers
    • 4.3.2.1 List Of Key Customers
  • 4.3.3 Public Companies
    • 4.3.3.1 List Of Public Companies
  • 4.3.4 Private Companies
    • 4.3.4.1 List Of Key Private Companies
  • 4.3.5 Emerging Players
    • 4.3.5.1 List Of Key Emerging Companies
• 4.4 Major Deals And Strategic Alliances Analysis
  • 4.4.1 Mergers And Acquisitions
  • 4.4.2 Collaborations And Partnerships
  • 4.4.3 Regional Expansion
  • 4.4.4 New Product Launch
• 4.5 Pricing Analysis
  • 4.5.1 Dnases: Liquid Form
  • 4.5.2 Dnases: Lyophilized Form
• 4.6 Company Market Positioning Analysis, 2021
  • 4.6.1 Dnases
  • 4.6.2 Key Parameters
    • 4.6.2.1 Company size
    • 4.6.2.2 Geographic presence and Distribution network
    • 4.6.2.3 Product portfolio
    • 4.6.2.4 Collaborations
• 4.7 Company Profiles: DNases Market
  • 4.7.1 THERMO FISHER SCIENTIFIC, INC.
    • 4.7.1.1 Company overview
    • 4.7.1.2 Financial Performance
    • 4.7.1.3 Product benchmarking
    • 4.7.1.4 Strategic initiatives
  • 4.7.2 MERCK KGAA
    • 4.7.2.1 Company overview
    • 4.7.2.1.1 Sigma-Aldrich Co. LLC
    • 4.7.2.2 Financial Performance
    • 4.7.2.3 Product benchmarking
    • 4.7.2.4 Strategic initiatives
  • 4.7.3 AGILENT TECHNOLOGIES, INC.
    • 4.7.3.1 Company Overview
    • 4.7.3.2 Financial Performance
    • 4.7.3.3 Product benchmarking
    • 4.7.3.4 Strategic initiatives
  • 4.7.4 PROMEGA CORPORATION.
    • 4.7.4.1 Company overview
    • 4.7.4.2 Financial Performance
    • 4.7.4.3 Product benchmarking
  • 4.7.5 QIAGEN N.V.
    • 4.7.5.1 Company Overview
    • 4.7.5.2 Financial Performance
    • 4.7.5.3 Product benchmarking
  • 4.7.6 RAYBIOTECH LIFE, INC.
    • 4.7.6.1 Company Overview
    • 4.7.6.2 Product benchmarking
  • 4.7.7 TAKARA BIO INC.
    • 4.7.7.1 Company Overview
    • 4.7.7.2 Financial Performance
    • 4.7.7.3 Product benchmarking
  • 4.7.8 ABNOVA CORPORATION
    • 4.7.8.1 Company Overview
    • 4.7.8.2 Financial Performance
    • 4.7.8.3 Product benchmarking
  • 4.7.9 NEW ENGLAND BIOLABS
    • 4.7.9.1 Company Overview
    • 4.7.9.2 Product benchmarking
    • 4.7.9.3 Strategic initiatives
  • 4.7.10 CALZYME
    • 4.7.10.1 Company Overview
    • 4.7.10.2 Product benchmarking
  • 4.7.11 BIOVISION INC.
    • 4.7.11.1 Company Overview
    • 4.7.11.2 Product benchmarking
    • 4.7.11.3 Strategic initiatives
  • 4.7.12 Articzymes Technologies Asa
    • 4.7.12.1 Company Overview
    • 4.7.12.2 Product Benchmarking
  • 4.7.13 Worthington Biochemical Corporation
    • 4.7.13.1 Company Overview
    • 4.7.13.2 Product Benchmarking

Chapter 5 Ligases Market: Application Business Analysis

• 5.1 Definitions & Scope
• 5.2 Ligases Market: Application Trend Analysis
• 5.3 Ligases Market: Application Movement Analysis
• 5.4 Oligonucleotide Synthesis
  • 5.4.1 Oligonucleotide Synthesis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.5 Other Applications
  • 5.5.1 Other Applications Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Ligases Market Competitive Landscape

• 6.1 Market Participation Categorization
• 6.2 Strategy Framework
• 6.3 Vendor Landscape
  • 6.3.1 List Of Key Distributors And Channel Partners
  • 6.3.2 Key Customers
    • 6.3.2.1 List Of Key Customers
  • 6.3.3 Public Companies
    • 6.3.3.1 List Of Public Companies
  • 6.3.4 Private Companies
    • 6.3.4.1 List Of Key Private Companies
  • 6.3.5 Emerging Players
    • 6.3.5.1 List Of Key Emerging Companies
• 6.4 Major Deals And Strategic Alliances Analysis
  • 6.4.1 Regional Expansion
  • 6.4.2 Collaborations And Partnerships
  • 6.4.3 Mergers And Acquisitions
• 6.5 Pricing Analysis
  • 6.5.1 Ligases: Liquid Form
  • 6.5.2 Ligases: Lyophilized Form
• 6.6 Company Market Positioning Analysis, 2021
  • 6.6.1 Ligases
  • 6.6.2 Key Parameters
    • 6.6.2.1 Company size
    • 6.6.2.2 Geographic presence and Distribution network
    • 6.6.2.3 Product portfolio
    • 6.6.2.4 Collaborations
• 6.7 Company Profiles: Ligases Market
  • 6.7.1 THERMO FISHER SCIENTIFIC, INC.
    • 6.7.1.1 Company overview
    • 6.7.1.2 Financial Performance
    • 6.7.1.3 Product benchmarking
    • 6.7.1.4 Strategic initiatives
  • 6.7.2 NEW ENGLAND BIOLABS
    • 6.7.2.1 Company Overview
    • 6.7.2.2 Product benchmarking
  • 6.7.3 PROMEGA CORPORATION.
    • 6.7.3.1 Company overview
    • 6.7.3.2 Financial Performance
    • 6.7.3.3 Product benchmarking
  • 6.7.4 AGILENT TECHNOLOGIES, INC.
    • 6.7.4.1 Company Overview
    • 6.7.4.2 Financial Performance
    • 6.7.4.3 Product benchmarking
  • 6.7.5 BIOVISION INC.
    • 6.7.5.1 Company Overview
    • 6.7.5.2 Product benchmarking
  • 6.7.6 BLIRT
    • 6.7.6.1 Company Overview
    • 6.7.6.2 Financial Performance
    • 6.7.6.3 Product benchmarking
    • 6.7.6.4 Strategic initiatives
  • 6.7.7 RAYBIOTECH LIFE, INC.
    • 6.7.7.1 Company Overview
    • 6.7.7.2 Financial Performance
    • 6.7.7.3 Product benchmarking
  • 6.7.8 ABCLONAL, INC.
    • 6.7.8.1 Company Overview
    • 6.7.8.2 Product benchmarking
    • 6.7.8.3 Strategic initiatives
  • 6.7.9 MBL INTERNATIONAL
    • 6.7.9.1 Company Overview
    • 6.7.9.2 Financial Performance
    • 6.7.9.3 Product benchmarking
  • 6.7.10 MYBIOSOURCE
    • 6.7.10.1 Company Overview
    • 6.7.10.2 Financial Performance
    • 6.7.10.3 Product benchmarking

Chapter 7 RNA Polymerases Market: Application Business Analysis

• 7.1 Definitions & Scope
• 7.2 RNA Polymerases Market: Application Trend Analysis
• 7.3 RNA Polymerases Market: Application Movement Analysis
• 7.4 mRNA Production
  • 7.4.1 mRNA Production Market Estimates And Forecasts, 2018- 2030 (USD Million)
• 7.5 Other Applications
  • 7.5.1 Other Applications Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 RNA Polymerases Market: Competitive Landscape

• 8.1 Market Participation Categorization
• 8.2 Strategy Framework
• 8.3 Vendor Landscape
  • 8.3.1 List Of Key Distributors And Channel Partners
  • 8.3.2 Key Customers
    • 8.3.2.1 List Of Key Customers
  • 8.3.3 Public Companies
    • 8.3.3.1 List Of Public Companies
  • 8.3.4 Private Companies
    • 8.3.4.1 List Of Key Private Companies
  • 8.3.5 Emerging Players
    • 8.3.5.1 List of key emerging companies
• 8.4 Major Deals and Strategic Alliances Analysis
  • 8.4.1 Collaborations And Partnerships
  • 8.4.2 Mergers And Acquisitions
  • 8.4.3 Regional Expansion
• 8.5 Pricing Analysis
  • 8.5.1 RNA Polymerases: Liquid Form
  • 8.5.2 RNA Polymerases: Lyophilized Form
• 8.6 Company Market Positioning Analysis, 2021
  • 8.6.1 Rna Polymerases
  • 8.6.2 Key Parameters
    • 8.6.2.1 Company size
    • 8.6.2.2 Geographic presence and Distribution network
    • 8.6.2.3 Product portfolio
    • 8.6.2.4 Collaborations
• 8.7 Company Profiles: RNA Polymerases Market
  • 8.7.1 AGILENT TECHNOLOGIES, INC.
    • 8.7.1.1 Company Overview
    • 8.7.1.2 Financial Performance
    • 8.7.1.3 Product benchmarking
    • 8.7.1.4 Strategic initiatives
  • 8.7.2 NEW ENGLAND BIOLABS
    • 8.7.2.1 Company Overview
    • 8.7.2.2 Product benchmarking
    • 8.7.2.3 Strategic initiatives
  • 8.7.3 PROMEGA CORPORATION
    • 8.7.3.1 Company overview
    • 8.7.3.2 Financial Performance
    • 8.7.3.3 Product benchmarking
    • 8.7.3.4 Strategic initiatives
  • 8.7.4 THERMO FISHER SCIENTIFIC, INC.
    • 8.7.4.1 Company overview
    • 8.7.4.2 Financial Performance
    • 8.7.4.3 Product benchmarking
    • 8.7.4.4 Strategic initiatives
  • 8.7.5 RAYBIOTECH LIFE, INC.
    • 8.7.5.1 Company Overview
    • 8.7.5.2 Financial Performance
    • 8.7.5.3 Product benchmarking
  • 8.7.6 BIORBYT LTD.
    • 8.7.6.1 Company Overview
    • 8.7.6.2 Financial Performance
    • 8.7.6.3 Product benchmarking
  • 8.7.7 MYBIOSOURCE
    • 8.7.7.1 Company Overview
    • 8.7.7.2 Financial Performance
    • 8.7.7.3 Product benchmarking
  • 8.7.8 BPS BIOSCIENCE, INC.
    • 8.7.8.1 Company Overview
    • 8.7.8.2 Financial Performance
    • 8.7.8.3 Product benchmarking
  • 8.7.9 SINO BIOLOGICAL INC.
    • 8.7.9.1 Company Overview
    • 8.7.9.2 Product benchmarking
  • 8.7.10 NOVUS BIOLOGICALS
    • 8.7.10.1 Company Overview
    • 8.7.10.2 Financial Performance
    • 8.7.10.3 Product benchmarking

Chapter 9 DNases, Ligases, RNA Polymerases Market: Regional Business Analysis

• 9.1 Market Share Analysis by Country, 2021 & 2030
  • 9.1.1 North America
    • 9.1.1.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.1.2 U.S.
    • 9.1.1.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.1.3 Canada
    • 9.1.1.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.1.2 Europe
    • 9.1.2.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.2.2 U.K.
    • 9.1.2.2.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.2.3 Germany
    • 9.1.2.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.2.4 France
    • 9.1.2.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.2.5 Italy
    • 9.1.2.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.2.6 Spain
    • 9.1.2.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.1.3 Asia-Pacific
    • 9.1.3.1 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.3.2 Japan
    • 9.1.3.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.3.3 China
    • 9.1.3.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.3.4 India
    • 9.1.3.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.3.5 Singapore
    • 9.1.3.5.1 Singapore Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.3.6 Australia
    • 9.1.3.6.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.1.4 Latin America
    • 9.1.4.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.4.2 Brazil
    • 9.1.4.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.4.3 Mexico
    • 9.1.4.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.4.4 Argentina
    • 9.1.4.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.1.5 Middle East And Africa
    • 9.1.5.1 Middle East & Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.5.2 South Africa
    • 9.1.5.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.5.3 Saudi Arabia
    • 9.1.5.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.1.5.4 UAE
    • 9.1.5.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)